• Explore /
  • Poster
  • / KEYNOTE-365 cohort I: Phase 1b/2 study of pembrolizumab combined with platinum-containing chemotherapy and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE).

KEYNOTE-365 cohort I: Phase 1b/2 study of pembrolizumab combined with platinum-containing chemotherapy and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE).

Abstract Poster

Authors

null

Johann S. De Bono

The Royal Marsden NHS Foundation Trust, London, United Kingdom

Johann S. De Bono , Anthony M. Joshua , Neal D. Shore , Gero Kramer , Xin Tong Li , Christian Heinrich Poehlein , Charles Schloss , Evan Y. Yu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02861573

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr TPS218)

DOI

10.1200/JCO.2022.40.6_suppl.TPS218

Abstract #

TPS218

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Evan Y. Yu

First Author: Gero Kramer

First Author: Evan Y. Yu

First Author: Peter C.C. Fong